Citizens Capital Markets Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $18

Benzinga · 03/12 15:15
Citizens Capital Markets analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $17 to $18.